In Vivo Efficacy Models CROs in China
8 published
8 published CROs match In Vivo Efficacy Models in China.
Locations in this set include China, United States, United Kingdom, Australia, Denmark, and Japan.
Capabilities that show up most often in this set: Antibody-Drug Conjugate (ADC), Biologics (Monoclonal Antibodies), Small Molecule, Biologics (Other), and Cell Therapy.
Matching companies
ChemDivChemDiv is a fully integrated target-to-clinic CRO headquartered in San Diego, CA, offering drug discovery services including medicinal chemistry, CADD, ADME/DMPK, toxicology, and custom synthesis alongside the industry's largest commercial screening library of 1.6M compounds.
ChemPartnerGlobal preclinical CRO with 20+ years of experience supporting drug discovery through IND submission across small molecules and biologics, with 2,000+ scientists and facilities worldwide.
Crown BiosciencePreclinical oncology CRO offering 2,500+ PDX models, organoid and cell line databases, and translational platforms with biomarker discovery and AI-driven systems biology for drug development.
GemPharmatechGemPharmatech develops and supplies genetically engineered mouse models (GEMMs) and preclinical research services using CRISPR/Cas9 and gene-editing technologies, with a library of 25,000+ mouse strains including KO/cKO, humanized, and immunodeficient models.
LIDE BiotechOncology-focused preclinical CRO with AAALAC-accredited China-based labs offering 2300+ PDX models, MiniPDX organoid assays, and multi-omics analysis for drug discovery and development.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
TigermedLeading global CRO providing end-to-end clinical trial services, preclinical development, medical device and IVD trials, regulatory affairs, and real-world evidence studies across 180+ offices serving 4,000+ customers.
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /services/in-vivo-efficacy-models/china.md